

## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	30 October 2023
Director or senior manager giving disclosure	
Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified deriva	itives)
	a) Options to acquire Ordinary Shares
Class of affected quoted financial products:	b) Performance Share Rights
	c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
_ ,, , , ,, ,	
For that relevant interest-	a) 117,027 Options
Number held in class before acquisition or disposal:	b) 58,850 Performance Share Rights
	c) 103,538 Ordinary Shares
	a) 144,531 Options
Number held in class after acquisition or disposal:	b) 49,717 Performance Share Rights c) 122,822 Ordinary Shares
Current registered holder(s):	
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell
registered floider(s) office transfers are registered.	Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if app Type of affected derivative:	plicable)
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	
	a) 11 September 2024
Data of transactions	b) 11 September 2024
Date of transaction:	c) 16 September 2024

	a) Issue of Options
	b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and
Nature of transaction:	issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	loode of Ordinary Orlares
The consideration, expressed in New Zealand dollars, paid or received for the	a) Nil
acquisition or disposal. If the consideration was not in cash and cannot be readily by	b) Nil
converted into a cash value, describe the consideration:	c) Nil
	a) 27,504 Options
	b) 10,151 Performance Share Rights
Number of financial was ducto to subject the two position valets de-	c) Exercise of 19,284 Performance Share Rights and issue of 19,284 Ordinary Shares
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior	and issue of 19,204 Ordinary Shares
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
•	•
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
	L
For that relevant interest,-  Number held in class:	
Current registered holder(s):	
For a derivative relevant interest	
Type of derivative:	
Type of defivative.	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Palline themand
Date of signature:	17 September 2024
Name and title of authorised person:	Raelene Leonard,
Traine and the or admonsed person.	General Counsel & Company Secretary



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	12 September 2024
	<u> </u>
Director or senior manager giving disclosure	
Full name(s):	Andrew Grant Niccol
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Operating Officer
	Officer Operating Officer
Summary of acquisition or disposal of relevant interest (excluding specified deriva	atives)
duminary of acquisition of disposal of relevant interest (excluding specified acrive	·
Class of affected quoted financial products:	a) Options to acquire Ordinary Shares     b) Performance Share Rights
Class of affected quoted financial products.	c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest-	
	a) 25,066 Options
Number held in class before acquisition or disposal:	b) 10,497 Performance Share Rights
	c) 3,150 Ordinary Shares a) 34,587 Options
Number held in class after acquisition or disposal:	b) 12,011 Performance Share Rights
realises field in oldes direct dequisition of disposal.	c) 4,500 Ordinary Shares
Current registered holder(s):	Andrew Grant Niccol
Registered holder(s) once transfers are registered:	Andrew Grant Niccol
Summary of acquisition or disposal of specified derivatives relevant interest (if app	nlicable)
	piicable)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the	
underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Four
Details of transactions requiring disclosure-	
. <b>.</b>	a) 11 September 2024
	b) 11 September 2024
	c) 11 September 2024
Date of transaction:	d) 16 September 2024

	General Counsel & Company Secretary
Name and title of authorised person:	General Counsel & Company Secretary
	17 September 2024 Raelene Leonard,
Date of signature:	
Signature of person authorised to sign on behalf of director or officer:	Palline themand
OF .	J L
Date of signature:	
Signature of director or officer:	1
persons for whom it is made.	+ -
disclosure is correct and that I am duly authorised to make this disclosure by all	
I, certify that, to the best of my knowledge and belief, the information contained in this	٦
Certification	
posterior medical delitration	J
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
For that derivative relevant interest,- Parties to the derivative:	+
underlying financial products:	+
under the derivative or the value of the derivative is affected by the value of the	
Any other details needed to understand how the amount of the consideration payable	1
The price's specified terms (if any):	1
Expiry date of the derivative (if any):	1
Maturity date of the derivative (if any):	1
A statement as to whether the derivative is cash settled or physically settled:	1
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
Details of derivative,-	1
Type of delivative.	
For a derivative relevant interest,- Type of derivative:	
Current registered holder(s):	
Number held in class:	
For that relevant interest,-	
Nature of relevant interest:	
Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:	7
	1 [
proceed during the closed period:  Date of the prior written clearance (if any):	1
Whether prior written clearance was provided to allow the acquisition or disposal to	
Whether relevant interests were acquired or disposed of during a closed period:	
include the following details—	
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period)	
Number of financial products to which the transaction related:	and issue of 2,000 Ordinary Shares
	c) 650 Ordinary Shares d) Exercise of 2,000 Performance Share Rights
	b) 3,514 Performance Share Rights
CONTROL III O a Cashi value, describe the consideration.	d) Nil a) 9,521 Options
acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	c) NZD 37.56 per Ordinary Share
The consideration, expressed in New Zealand dollars, paid or received for the	b) Nil
Name of any other party or parties to the transaction (if known):	a) Nil
Nature of transaction:	issue of Ordinary Shares
	c) Sale of Ordinary Shares d) Exercise of Performance Share Rights and
	b) Issue of Performance Share Rights
	a) Issue of Options



#### Disclosure of Directors and Senior Managers Relevant Interests

managers from trading during any period without written clearance (a closed period)

include the following details-

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	26 June 2024
<b>-</b>	
Director or senior manager giving disclosure	0.1
Full name(s):  Name of listed issuer:	Graham Andrew McLean
	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director
Summary of acquisition or disposal of relevant interest (excluding specified derivate	tives)
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
	Santa and an analysis of the santa analysis of the
For that relevant interest-	
Number held in class before acquisition or disposal:	1,100 Ordinary Shares
Number held in class after acquisition or disposal:	1,900 Ordinary Shares
Current registered holder(s):	Graham Andrew McLean and Linda Farrell as
	trustees of McLean Superfund A/C Graham Andrew McLean and Linda Farrell as
Registered holder(s) once transfers are registered:	trustees of McLean Superfund A/C
Summary of acquisition or disposal of specified derivatives relevant interest (if app  Type of affected derivative:	licable)
Class of underlying financial products:	
Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	12 September 2024
Nature of transaction:	Purchase of Ordinary Shares
Name of any other party or parties to the transaction (if known):	·
The consideration, expressed in New Zealand dollars, paid or received for the	
acquisition or disposal. If the consideration was not in cash and cannot be readily by	
converted into a cash value, describe the consideration:	AUD 34.915 per Ordinary Share
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior	800 Ordinary Shares
n are resear has a linaricial products dading policy that profibits difectors of Serilor	

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:  Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Type of defivative.	L
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying	
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all	
persons for whom it is made.  Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Palline theward
Date of signature:	17 September 2024
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	12 September 2024
Director or senior manager giving disclosure	
Full name(s):	Justin Peter Callahan
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified deriva	
Class of affected quoted financial products:	a) Options to acquire Ordinary Shares     b) Performance Share Rights     c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest-	a) 98,992 Options
Number held in class before acquisition or disposal:	b) 42,879 Performance Share Rights c) 168,371 Ordinary Shares a) 136,658 Options
Number held in class after acquisition or disposal:	b) 49,367 Performance Share Rights c) 175,785 Ordinary Shares
Current registered holder(s):	Justin Peter Callahan
Registered holder(s) once transfers are registered:	Justin Peter Callahan
Summary of acquisition or disposal of specified derivatives relevant interest (if appropriate the second sec	plicable)
olass of underlying infantial products.	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	
Date of transaction:	a) 11 September 2024 b) 11 September 2024 c) 17 September 2024

	a) Issue of Options
	b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and
Nature of transaction:	issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	loode of Ordinary Orlares
The consideration, expressed in New Zealand dollars, paid or received for the	a) Nil
acquisition or disposal. If the consideration was not in cash and cannot be readily by	b) Nil
converted into a cash value, describe the consideration:	c) Nil
	a) 37,666 Options
	b) 13,902 Performance Share Rights
Number of financial products to which the transaction related:	c) Exercise of 7,414 Performance Share Rights and issue of 7,414 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior	and issue of 1,414 Ordinary offaces
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
	•
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	<u></u>
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying	
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	-
Signature of person authorised to sign on behalf of director or officer:	Palene therand
	7
Date of signature:	17 September 2024 Raelene Leonard,
Name and title of authorised person:	General Counsel & Company Secretary



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	12 September 2024
	· · · · · · · · · · · · · · · · · · ·
Director or senior manager giving disclosure	
Full name(s):	Lewis George Gradon
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Freevitive Officer
1 Collient Hold III Holde I Coder.	Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified deriva	<u></u>
Class of affected quoted financial products:	a) Options to acquire Ordinary Shares     b) Performance Share Rights     o) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest-	
Number held in class before acquisition or disposal:	a) 385,512 Options b) 172,025 Performance Share Rights c) 576,317 Ordinary Shares
Number held in class after acquisition or disposal:	a) 470,992 Options b) 159,726 Performance Share Rights c) 620,165 Ordinary Shares
Current registered holder(s):	a) Lewis George Gradon     b) Lewis George Gradon     c) Lewis George Gradon; Gradon Family Trust
Registered holder(s) once transfers are registered:	a) Lewis George Gradon     b) Lewis George Gradon     c) Lewis George Gradon; Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if app	plicable)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three

Details of transactions requiring disclosure-	
	a) 11 September 2024
Data of transport	b) 11 September 2024
Date of transaction:	c) 13 September 2024 a) Issue of Options
	b) Issue of Performance Share Rights
	c) Exercise of Performance Share Rights and
Nature of transaction:	issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the	a) Nil
acquisition or disposal. If the consideration was not in cash and cannot be readily by	b) Nil
converted into a cash value, describe the consideration:	c) Nil a) 85,480 Options
	b) 31,549 Performance Share Rights
	c) Exercise of 43,848 Performance Share Rig
Number of financial products to which the transaction related:	and issue of 43,848 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Number held in class: Current registered holder(s):	
Number held in class:	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:	
Number held in class:  Current registered holder(s):  For a derivative relevant interest,-  Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:  Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
Number held in class: Current registered holder(s): For a derivative relevant interest,-	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:  Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any):	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any):	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative;  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:  Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	
Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative.  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative.  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative.  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative.  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative;  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  or	Palene manal
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative;  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  or	
Number held in class: Current registered holder(s):  For a derivative relevant interest,- Type of derivative.  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:	Paller Marcal  17 September 2024 Raelene Leonard,



## **Disclosure of Directors and Senior Managers Relevant Interests**

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	12 September 2024
Director or senior manager giving disclosure	
Full name(s):	Lyndal Jane York
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer
	Office Financial Office.
Summary of acquisition or disposal of relevant interest (excluding specified deriva	itives)
	a) Options to acquire Ordinary Shares
Class of affected quoted financial products:	b) Performance Share Rights
Nature of the affected relevant interest(s):	c) Ordinary Shares
Nature of the affected relevant interest(s).	Beneficial Interest
For that relevant interest-	
For that relevant interest-	a) 159,843 Options
Number held in class before acquisition or disposal:	b) 67,840 Performance Share Rights
	c) 17,119 Ordinary Shares
No make and the place of the committee and the combination of	a) 203,534 Options
Number held in class after acquisition or disposal:	b) 74,560 Performance Share Rights c) 26,525 Ordinary Shares
	a) Lyndal Jane York
Current registered holder(s):	b) Lyndal Jane York
	c) Lyndal Jane York and Alexander Eric York
Registered holder(s) once transfers are registered:	a) Lyndal Jane York b) Lyndal Jane York
registered floider(s) office transfers are registered.	c) Lyndal Jane York and Alexander Eric York
Summary of acquisition or disposal of specified derivatives relevant interest (if app	nlicable)
Summary of acquisition of disposal of specified derivatives relevant interest (if app	plicable)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying	
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
,	
For that derivative,- Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the	
relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	
	a) 11 September 2024
Date of transaction:	b) 11 September 2024 c) 16 September 2024
Nature of transaction:	a) Issue of Options
	b) Issue of Performance Share Rights
	c) Exercise of Performance Share Rights and
	issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the	a) Nil
acquisition or disposal. If the consideration was not in cash and cannot be readily by	b) Nil
converted into a cash value, describe the consideration:	c) Nil a) 43,691 Options
	b) 16,126 Performance Share Rights
	c) Exercise of 9,406 Performance Share Rights
Number of financial products to which the transaction related:	and issue of 9,406 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
1 ( 7/	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cartification	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Palline theward
Date of signature:	17 September 2024
Name and title of authorised person:	Raelene Leonard,
That is also of desironous porton.	General Counsel & Company Secretary



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	17 September 2024
Date of last disclosure:	12 September 2024
Director or senior manager giving disclosure	
Full name(s):	Paul Nigel Shearer
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	International Sales Director
Summary of acquisition or disposal of relevant interest (excluding specified deriv	atives)
Class of affected quoted financial products:	a) Options to acquire Ordinary Shares     b) Performance Share Rights     c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest-	I []
Number held in class before acquisition or disposal:	a) 194,686 Options b) 86,075 Performance Share Rights c) 397,001 Ordinary Shares
Number held in class after acquisition or disposal:	a) 201,055 Options b) 67,632 Performance Share Rights c) 417,795 Ordinary Shares
Current registered holder(s):	a) Paul Nigel Shearer     b) Paul Nigel Shearer     c) Paul Nigel Shearer; Shearer Family Trust
Registered holder(s) once transfers are registered:	a) Paul Nigel Shearer     b) Paul Nigel Shearer     c) Paul Nigel Shearer; Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if ap	oplicable)
Type of affected derivative:	
Class of underlying financial products:	
older of andonying mandal produce.	l L
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Take the state of the st	12

Details of transactions requiring disclosure-	
	a) 11 September 2024 b) 11 September 2024
Date of transaction:	c) 16 September 2024 a) Issue of Options
	b) Issue of Performance Share Rights
	c) Exercise of Performance Share Rights and
Nature of transaction:	issue of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by	a) Nil b) Nil
converted into a cash value, describe the consideration:	c) Nil
Number of financial products to which the transaction related:	a) 6,369 Options
	b) 2,351 Performance Share Rights c) Exercise of 20,794 Performance Share Rights
	and issue of 20,794 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:  Nature of relevant interest:	
For that relevant interest,- Number held in class:	<b>—</b>
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying	
Type of derivative:  Details of derivative,-	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-	
Type of derivative:  Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the	
Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all	
Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all	
Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:	
Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:	
Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:	S S
Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:	Palene travard